Table 1.
SLE patient characteristics and relative IFNβ mRNA level
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | |
---|---|---|---|---|---|---|
Ethnicity | AA | C | C | C | AA | AA |
Age | 33 | 57 | 50 | 46 | 64 | 33 |
Age of paired healthy donor | 31 | 58 | 51 | 44 | 59 | 36 |
Sex | F | F | F | F | F | F |
Passage | 2 | 2 | 2 | 2 | 2 | 2 |
Total SLEDAI Score | 6 | 6 | 2 | 7 | 0 | 2 |
anti-RNP (nl 0.0–0.9) | >7.3 | 3.3 | N.D.* | 1.2 | <0.2 | >8.0 |
anti-Sm (nl 0.0–0.9) | >8.0 | 0.2 | N.D.* | >8.0 | <0.2 | <0.2 |
anti-SM/RNP (nl 0.0–0.9) | >8.0 | >8.0 | N.D.* | >8.0 | <0.2 | 1.2 |
anti-Ro (nl 0.0–0.9) | >8.0 | <0.2 | 7.4 | >8.0 | <0.2 | >8.0 |
anti-La (nl 0.0–0.9) | 1.5 | <0.2 | 2 | 1.6 | <0.2 | 0.5 |
anti-DNA (nl 0–4 U/mL) | 17 | 14 | 194 | 24 | 3 | <1 |
C3 (nl 90–180 mg/dL) | 84 | 129 | 120 | 80 | 97 | 151 |
C4 (nl 10–40 mg/dL) | 15 | 21 | 31 | 9 | 31 | 31 |
Relative IFNβ mRNA level compared to healthy controls (fold change) | 3.4 | 3.1 | 2.7 | 4.3 | 1.7 | 2.9 |
Not determined.